Centessa Pharmaceuticals (NASDAQ:CNTA) CEO Mario Alberto Accardi told attendees at Guggenheim’s 2026 Emerging Outlook Biotech Summit that 2026 is “shaping up to be a transformational year” for the company as it moves its lead orexin agonist program toward registrational studies in rare hypersomnias and advances a next-generation asset into the clinic. Positioning ORX750 for registrational […]